Imugene Stock EBITDA
| IMU Stock | 0.04 0 2.56% |
Imugene fundamentals help investors to digest information that contributes to Imugene's financial success or failures. It also enables traders to predict the movement of Imugene Stock. The fundamental analysis module provides a way to measure Imugene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Imugene stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -148 M | -140.6 M |
Imugene | EBITDA |
Imugene Company EBITDA Analysis
Imugene's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Imugene EBITDA | (147.98 M) |
Most of Imugene's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Imugene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Imugene Ebitda
Ebitda |
|
According to the company disclosure, Imugene reported earnings before interest,tax, depreciation and amortization of (147.98 Million). This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The ebitda for all Australia stocks is notably higher than that of the company.
Imugene EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Imugene's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Imugene could also be used in its relative valuation, which is a method of valuing Imugene by comparing valuation metrics of similar companies.Imugene is currently under evaluation in ebitda category among its peers.
Imugene Fundamentals
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.51 | ||||
| Operating Margin | 22.86 % | ||||
| Current Valuation | 195.99 M | ||||
| Shares Outstanding | 7.57 B | ||||
| Shares Owned By Insiders | 14.38 % | ||||
| Shares Owned By Institutions | 6.64 % | ||||
| Price To Book | 2.43 X | ||||
| Price To Sales | 62.42 X | ||||
| Revenue | 4.97 M | ||||
| Gross Profit | 11.78 M | ||||
| EBITDA | (147.98 M) | ||||
| Net Income | (149.68 M) | ||||
| Cash And Equivalents | 49.54 M | ||||
| Total Debt | 1.55 M | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (97.32 M) | ||||
| Earnings Per Share | (0.02) X | ||||
| Target Price | 0.3 | ||||
| Beta | 3.34 | ||||
| Market Capitalization | 310.25 M | ||||
| Total Asset | 151.4 M | ||||
| Retained Earnings | (289.83 M) | ||||
| Working Capital | 83.74 M | ||||
| Net Asset | 151.4 M |
About Imugene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Imugene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Imugene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Imugene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Imugene Stock Analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.